Celcuity (CELC) Income from Continuing Operations (2016 - 2025)
Celcuity (CELC) posted Income from Continuing Operations of 50973000.0 for Q4 2025, down 16.37% on a QoQ basis from 43804000.0 in Q3 2025, and down 39.07% year-over-year from 83657071.11 in Q4 2024.
Celcuity (CELC) Income from Continuing Operations (2016 - 2025) Analysis & Trends
Celcuity's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 50973000.0 for Q4 2025.
- Quarterly Income from Continuing Operations fell 39.07% year-over-year to 50973000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 177042000.0 (down 58.39% YoY) and the FY2025 annual result came in at 139863000.0, down 24.38% from the prior year.
- Income from Continuing Operations was 50973000.0 for Q4 2025 at Celcuity, down from 43804000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2791668.0 in Q1 2021 and bottomed at 50973000.0 in Q4 2025.
- A 5-year average of 21128771.1 and a median of 16496113.5 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations sank 1104.06% — and 2022, when it climbed 29.02%.
- Celcuity's Income from Continuing Operations stood at 6753500.0 in 2021, then slumped by 71.49% to 11581346.0 in 2022, then plunged by 62.75% to 18848472.0 in 2023, then slumped by 94.46% to 36653000.0 in 2024, then slumped by 39.07% to 50973000.0 in 2025.
- Business Quant data shows CELC's Income from Continuing Operations at 50973000.0 in Q4 2025, 43804000.0 in Q3 2025, and 45268000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Celcuity | 4.13 Bn | 4.13 Bn | - | -50.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -50.97 Mn |
| Sep 30, 2025 | -43.80 Mn |
| Jun 30, 2025 | -45.27 Mn |
| Mar 31, 2025 | -37.00 Mn |
| Dec 31, 2024 | -36.65 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -23.72 Mn |
| Mar 31, 2024 | -21.61 Mn |
| Dec 31, 2023 | -18.85 Mn |
| Sep 30, 2023 | -18.40 Mn |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | -11.94 Mn |
| Dec 31, 2022 | -11.58 Mn |
| Sep 30, 2022 | -10.89 Mn |
| Jun 30, 2022 | -9.96 Mn |
| Mar 31, 2022 | -7.93 Mn |
| Dec 31, 2021 | -6.75 Mn |
| Sep 30, 2021 | -6.03 Mn |
| Jun 30, 2021 | -14.03 Mn |
| Mar 31, 2021 | -2.79 Mn |